Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma

European Urology

Volumn 67, Issue 5, 2015, Pages 952-958

  Grünwald, Viktor ^a   McKay, Rana R ^b   Krajewski, Katherine M ^b,c   Kalanovic, Daniel ^d   Lin, Xun ^d   Perkins, Julia J ^d   Simantov, Ronit ^d   Choueiri, Toni K ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d PFIZER INC   (United States)

Author keywords

Imaging Prognosis; Renal cell carcinoma; Targeted therapy; Tumor response; Tumor shrinkage

Indexed keywords

ALPHA INTERFERON; AXITINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; ANTINEOPLASTIC AGENT;

AGED; ARTICLE; BONE METASTASIS; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT HISTORY OF NEPHRECTOMY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; CARCINOMA, RENAL CELL; COMPLICATION; DISEASE FREE SURVIVAL; FEMALE; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REMISSION; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84926149358     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.12.036     Document Type: Article

References (19)

1. A.M. Molina, X. Lin, and B. Korytowsky Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials Eur J Cancer 50 2014 351 358
2. J. Busch, C. Seidel, and I. Goranova Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma Eur J Cancer 50 2014 563 569
3. C. Seidel, J. Busch, S. Weikert, S. Steffens, C. Bokemeyer, and V. Grunwald Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC) Br J Cancer 109 2013 2998 3004
4. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
5. R.J. Motzer, M. Mazumdar, J. Bacik, W. Berg, A. Amsterdam, and J. Ferrara Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma J Clin Oncol. 17 1999 2530 2540
6. R.J. Motzer, C.H. Barrios, and T.M. Kim Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma J Clin Oncol. 32 2014 2765 2772
7. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
8. K.M. Krajewski, M. Guo, and A.D. Van den Abbeele Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma Eur Urol 59 2011 856 862
9. A. Stein, J. Bellmunt, and B. Escudier Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial Eur Urol 64 2013 994 1002
10. H. Piessevaux, M. Buyse, and M. Schlichting Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab J Clin Oncol 31 2013 3764 3775
11. M. Nishino, S.E. Dahlberg, and S. Cardarella Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI J Thorac Oncol 8 2013 1059 1068
12. J.R. Anderson, K.C. Cain, and R.D. Gelber Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables J Clin Oncol 26 2008 3913 3915
13. J.R. Anderson, K.C. Cain, and R.D. Gelber Analysis of survival by tumor response J Clin Oncol 1 1983 710 719
14. H. Choi, C. Charnsangavej, and S.C. Faria Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 2007 1753 1759
15. M. Lamuraglia, B. Escudier, and L. Chami To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound Eur J Cancer 42 2006 2472 2479
16. K.T. Flaherty, M.A. Rosen, and D.F. Heitjan Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma Cancer Biol Ther 7 2008 496 501
17. L.E. Dodd, E.L. Korn, and B. Freidlin Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol 26 2008 3791 3796
18. O. Amit, F. Mannino, and A.M. Stone Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis Eur J Cancer 47 2011 1772 1778
19. S. Litiere, E.G. de Vries, and L. Seymour The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database Eur J Cancer 50 2014 1847 1853